Remember when Moderna was the hottest ticket on Wall Street?
Then the Covid trade died.
And the stock quietly bled out for years.
Well… guess who's back.
Moderna is up nearly 150% in 2026.
One of the best-performing stocks in the entire S&P 500 — and one of the only top gainers that has nothing to do with AI or GPUs.
Even Jim Cramer just called it investable again.
At its peak in August 2021, Moderna traded near $484.
Then came the crash. The doubts. The "one-hit wonder" label.
For years, one question haunted the stock:
What comes after Covid?
Last week at Moderna's Science Day, the company finally gave a real answer — a decade-long roadmap built around one thing.
Cancer.
Moderna now has cancer therapies in mid- and late-stage trials across:
That's not a science experiment.
That's a pipeline.
And the crown jewel? A combo of Moderna's Intismeran + Merck's Keytruda for high-risk melanoma.
5-year data already showed it cut the risk of distant metastasis or death by 59% versus Keytruda alone.
The late-stage readout is landing later this year.
If it hits, this stock stops being about vaccines entirely.
While everyone was writing obituaries, Moderna quietly kept shipping:
The stock has ripped 20% just since Science Day.
He's not saying chase it.
He's saying: wait for a pullback.
"Moderna's got a bright future… but it'll take years to get there."
Translation? The story has changed.
This isn't the Covid trade anymore.
This isn't a value trap anymore.
It's a biotech with a real pipeline, real catalysts, and — for the first time in years — a real path to profitability.
The market loves a resurrection story.
But resurrections don't happen because the stock got cheap.
They happen when the business quietly rebuilds itself while nobody's watching.
Moderna spent three years being written off.
And used those three years to build what might be its second act.
That's all for now!
